Bavarian Nordic A/S (BV3.F)
- Previous Close
21.55 - Open
21.57 - Bid 21.90 x 10000
- Ask 22.34 x 10000
- Day's Range
21.57 - 22.11 - 52 Week Range
17.81 - 42.70 - Volume
90 - Avg. Volume
651 - Market Cap (intraday)
1.734B - Beta (5Y Monthly) 1.21
- PE Ratio (TTM)
9.74 - EPS (TTM)
2.25 - Earnings Date May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
www.bavarian-nordic.comRecent News: BV3.F
View MorePerformance Overview: BV3.F
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BV3.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BV3.F
View MoreValuation Measures
Market Cap
1.70B
Enterprise Value
1.55B
Trailing P/E
9.57
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.05
Price/Book (mrq)
1.08
Enterprise Value/Revenue
1.86
Enterprise Value/EBITDA
5.76
Financial Highlights
Profitability and Income Statement
Profit Margin
21.20%
Return on Assets (ttm)
6.65%
Return on Equity (ttm)
12.16%
Revenue (ttm)
6.23B
Net Income Avi to Common (ttm)
1.32B
Diluted EPS (ttm)
2.25
Balance Sheet and Cash Flow
Total Cash (mrq)
1.24B
Total Debt/Equity (mrq)
1.01%
Levered Free Cash Flow (ttm)
-2.87B